SBK Showcases Multiple Innovations at AHA 2025 and ACRE-cnAHA 2025 Symposium

The American Heart Association Scientific Sessions 2025 (AHA 2025) took place November 7–10 in New Orleans, Louisiana. As one of the world's premier gatherings in cardiovascular science and medicine, the meeting highlighted major advances across the field and drew tens of thousands of top researchers and clinicians from around the globe. Shibeikang (SBK) was invited to participate in AHA 2025 and will present a poster in the highly watched Late-Breaking Basic Science session.

During the same week, SBK also took part in the 2025 Cardiovascular Symposium co-hosted by ACRE-cnAHA, where the company delivered a keynote address highlighting the latest updates and strategic direction of its R&D pipeline to attending experts.

In addition, during the AHA 2025, SBK convened multiple internationally recognized experts for in-depth discussions on the evolving landscape and challenges in cardiovascular and thrombotic diseases from basic science and translational technologies to clinical practice. The dialogue aimed to spark collaboration across the field and leverage global expertise to accelerate both scientific progress and the company's growth.

Keynote Speech

On November 6, at the 2025 ACRE-cnAHA Symposium, the head of SBK's Medical Affairs Department delivered a keynote address titled "Shibeikang’s Current R&D Pipeline: Key Candidates and Development Status." The presentation highlighted the company's R&D pipeline strategy, recent scientific breakthroughs, and key milestones in clinical development. The presentation provided a detailed overview of the clinical progress and differentiated advantages of SBK002 (Becondogrel), a next-generation antiplatelet therapy. It also highlighted SBK's industry-leading metabolically differentiated R&D platform and its end-to-end capabilities for driving clinical translation. The talk drew strong interest and positive feedback from attending experts.

Poster Presentation

At AHA 2025, SBK was invited to debut the latest research of its next-generation antiplatelet innovative drug "SBK019", in the Late-Breaking Basic Science session through a poster presentation. The session offered a valuable opportunity to share new data with global experts and engage in meaningful scientific discussions. During the poster exchange, researchers held active discussions on SBK019's innovative molecular design and its key mechanism aimed at bypassing CYP450-dependent metabolism. Experts showed strong interest in the stability of SBK019's efficacy across populations with genetic polymorphisms and recognized its clinical value in the field of antiplatelet therapy. Particularly, they also highlighted the relevance of SBK019 in advancing personalized antiplatelet therapy for cardiovascular disease and improving real-world clinical outcomes.

Expert Interview

During the AHA 2025 conference, SBK invited multiple globally renowned experts in the cardiovascular field, including Professor Zhao Wang (Beckman Research Institute of City of Hope), Professor Tzung K. Hsiai (University of California, Los Angeles), Professor Xinliang Ma (Thomas Jefferson University), Professor Joseph A. Hill (University of Texas Southwestern Medical Center), and Professor Eugene Chen (University of Michigan), to engage in an in-depth discussion on the central theme: "Breaking New Ground in Antiplatelet Therapy: From Mechanism Exploration to Clinical Innovation." During the nearly 90-minute discussion, experts engaged in dialogue with the company around three key themes: "Resolving the Ischemia-Bleeding Dilemma," "Clinical Translation Pathways," and "A Vision for the Next Decade." Whether addressing "multi-target synergy," "intelligent drug design," or "spatiotemporal precision antithrombosis," these profound insights will provide invaluable guidance for industry advancement and the innovation of SBK's pipeline. This will further solidify SBK's R&D strengths and accelerate the development of innovative therapies that better meet clinical needs.

Expert Interview Venue (Left to Right): ：Tzung K. Hsiai、Zhao Wang、Xinliang Ma、Joseph A. Hill、Eugene Chen、SBK

The invitation to participate in AHA 2025 and the ACRE-cnAHA 2025 Symposium represents an acknowledgment that our independent innovation capabilities are gaining meaningful recognition from the global scientific community. Looking ahead, SBK will continue to deepen collaboration with research institutions, clinical experts, and industry partners at home and abroad. Together, we aim to advance technological innovation, strengthen industry development, and accelerate progress in the treatment of cardiovascular disease, bringing the strength of Chinese innovation to global health.